streptomycin ๐Ÿถ Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
antibiotics, produced by Streptomyces strains 2481 57-92-1

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • streptomycin
  • streptomycin sulfate
An antibiotic produced by the soil actinomycete Streptomyces griseus. It acts by inhibiting the initiation and elongation processes during protein synthesis.
  • Molecular weight: 581.58
  • Formula: C21H39N7O12
  • CLOGP: -3.46
  • LIPINSKI: 3
  • HAC: 19
  • HDO: 14
  • TPSA: 331.43
  • ALOGS: -1.66
  • ROTB: 9

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
1 g P

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 3 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 20 mg/mL Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 55 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 34.39 ยตM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 1 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 0.34 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 0.78 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.65 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 4.30 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
Feb. 18, 1946 FDA PFIZER

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Paradoxical drug reaction 65.14 45.12 13 437 3634 50601040
Drug reaction with eosinophilia and systemic symptoms 63.73 45.12 19 431 28405 50576269

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Paradoxical drug reaction 125.10 44.08 25 655 2716 29571131
Immune reconstitution inflammatory syndrome 84.34 44.08 22 658 7780 29566067
Tuberculoma of central nervous system 79.93 44.08 12 668 236 29573611
Immune reconstitution inflammatory syndrome associated tuberculosis 66.76 44.08 11 669 400 29573447

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Paradoxical drug reaction 179.97 39.38 37 1092 6083 64491520
Immune reconstitution inflammatory syndrome associated tuberculosis 90.28 39.38 15 1114 758 64496845
Tuberculoma of central nervous system 80.70 39.38 13 1116 541 64497062
Immune reconstitution inflammatory syndrome 79.92 39.38 22 1107 12448 64485155
Drug resistance 64.82 39.38 24 1105 35078 64462525
Drug reaction with eosinophilia and systemic symptoms 64.65 39.38 27 1102 54190 64443413
Drug-induced liver injury 57.71 39.38 24 1105 47619 64449984

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC A07AA04 ALIMENTARY TRACT AND METABOLISM
ANTIDIARRHEALS, INTESTINAL ANTIINFLAMMATORY/ANTIINFECTIVE AGENTS
INTESTINAL ANTIINFECTIVES
Antibiotics
ATC A07AA54 ALIMENTARY TRACT AND METABOLISM
ANTIDIARRHEALS, INTESTINAL ANTIINFLAMMATORY/ANTIINFECTIVE AGENTS
INTESTINAL ANTIINFECTIVES
Antibiotics
ATC J01GA01 ANTIINFECTIVES FOR SYSTEMIC USE
ANTIBACTERIALS FOR SYSTEMIC USE
AMINOGLYCOSIDE ANTIBACTERIALS
Streptomycins
ATC J04AM01 ANTIINFECTIVES FOR SYSTEMIC USE
ANTIMYCOBACTERIALS
DRUGS FOR TREATMENT OF TUBERCULOSIS
Combinations of drugs for treatment of tuberculosis
FDA CS M0000946 Aminoglycosides
FDA EPC N0000175477 Aminoglycoside Antibacterial
FDA EPC N0000175483 Antimycobacterial
MeSH PA D000900 Anti-Bacterial Agents
MeSH PA D000890 Anti-Infective Agents
MeSH PA D004791 Enzyme Inhibitors
MeSH PA D011500 Protein Synthesis Inhibitors
CHEBI has role CHEBI:33281 antibiotics
CHEBI has role CHEBI:36043 antimicrobial drugs
CHEBI has role CHEBI:36047 antibacterial drugs
CHEBI has role CHEBI:48001 protein synthesis inhibitors
CHEBI has role CHEBI:86328 anti-fungal agrichemical

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Tularemia indication 19265001
Acute tuberculosis indication 25629007
Granuloma inguinale indication 28867007 DOID:9113
Plague indication 58750007 DOID:3482
Klebsiella cystitis indication 60867007
Haemophilus influenzae pneumonia indication 70036007
Brucellosis indication 75702008 DOID:11077
Pulmonary tuberculosis indication 154283005 DOID:2957
Chancroid indication 266143009 DOID:13778
Escherichia coli urinary tract infection indication 301011002
Proteus urinary tract infection indication 301012009
Bacterial urinary infection indication 312124009
Aerobic Gram-Negative Bacteremia indication
Synergy for Streptococcal Endocarditis indication
Haemophilus Endocarditis indication
Synergy for Enterococcal Endocarditis indication
Enterococcus Urinary Tract Infection indication
Synergy for Enterococcal Infections indication
H. Influenzae Meningitis indication
Pulmonary Mycobacterium avium complex infection off-label use 186342000
Hypocalcemia contraindication 5291005
Parkinsonism contraindication 32798002
Dehydration contraindication 34095006
Tinnitus contraindication 60862001
Kidney disease contraindication 90708001 DOID:557
Myasthenia gravis contraindication 91637004 DOID:437
Pregnancy, function contraindication 289908002
Vertigo contraindication 399153001
Inner Ear Disturbance contraindication
Disorder of the 8th Cranial Nerve contraindication
Infant Botulism contraindication




๐Ÿถ Veterinary Drug Use

None

๐Ÿถ Veterinary products

ProductApplicantIngredients
Entromycin Powder Zoetis Inc. 2
STREP SOL Huvepharma EOOD 1
Streptomycin Oral Solution Huvepharma EOOD 1

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 12.43 acidic
pKa2 12.62 acidic
pKa3 13.36 acidic
pKa4 13.79 acidic
pKa5 11.91 Basic
pKa6 11.21 Basic
pKa7 6.49 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
30S ribosomal protein S12 Ribosomal protein WOMBAT-PK

External reference:

IDSource
4019933 VUID
N0000148018 NUI
D01350 KEGG_DRUG
3810-74-0 SECONDARY_CAS_RN
4017475 VANDF
4019933 VANDF
C0038425 UMLSCUI
CHEBI:58007 CHEBI
SRY PDB_CHEM_ID
CHEMBL372795 ChEMBL_ID
CHEMBL3184791 ChEMBL_ID
CHEMBL453087 ChEMBL_ID
D013307 MESH_DESCRIPTOR_UI
DB01082 DRUGBANK_ID
10923 IUPHAR_LIGAND_ID
3685 INN_ID
Y45QSO73OB UNII
19649 PUBCHEM_CID
10109 RXNORM
1794 MMSL
5514 MMSL
d00159 MMSL
002770 NDDF
004895 NDDF
387223008 SNOMEDCT_US
40877002 SNOMEDCT_US
73246001 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Streptomycin HUMAN PRESCRIPTION DRUG LABEL 1 39822-0706 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 1 g INTRAMUSCULAR ANDA 21 sections
Streptomycin HUMAN PRESCRIPTION DRUG LABEL 1 39822-0706 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 1 g INTRAMUSCULAR ANDA 21 sections